Sometimes the best investment opportunities hide in plain sight, buried under near-term headwinds that obscure longer-term potential. That's the thesis Bank of America is making for Bristol Myers Squibb (BMY), a pharmaceutical giant trading at what the firm calls "trough valuation" despite a research pipeline that could fuel the next growth cycle.
BofA Securities upgraded Bristol Myers from Neutral to Buy on Monday, boosting its price target from $52 to $61. The new target applies a 10x price-to-earnings multiple to fiscal 2027 earnings estimates, up from the previous 8x multiple applied to 2026 estimates.
"What we like about BMY is the valuation coupled with our forecast for a flattish 7-year outlook with risk-adjusted pipeline and favorable mix-related margin tailwinds," analyst Jason Gerberry wrote in an investor note. "When we factor in multiple pipeline-driven upside scenarios (specifically in '26E), we think the risk-reward is compelling."
Why the Stock Looks Cheap
Here's the situation: Bristol Myers is staring down patent cliffs as key products lose exclusivity, and investors have responded by slapping a sector-low multiple on the shares. But Gerberry argues this creates an opportunity rather than a trap. The stock is essentially priced for worst-case scenarios at trough earnings levels, which provides a floor. Meanwhile, the company's research pipeline contains 4-6 programs that could deliver meaningful catalysts in the near term.
"We believe now is an optimal entry point — BMY shares trade at a sector-low multiple due to impending product LOEs (loss of exclusivities), but we see a stock trading at a fair multiple of trough EPS under harsh assumptions," Gerberry noted.
The analyst's view is that strong pharma pipeline stories can work once investors gain visibility into the next product cycle. Bristol Myers is approaching a catalyst-rich 2026 with multiple scenarios that could position the company for a return to growth in 2029 and beyond.
Recent Developments and Outlook
Not everything has gone smoothly recently. In November, Bristol Myers and Johnson & Johnson (JNJ) stopped the Phase 3 Librexia ACS trial evaluating milvexian, a treatment for patients after acute coronary syndrome events. The companies discontinued the trial after assessing efficacy and safety data.
Still, Bristol Myers has maintained reasonably solid guidance. The drugmaker narrowed its fiscal 2025 earnings outlook from $6.35-$6.65 to $6.40-$6.60, compared to consensus expectations of $6.38. More notably, the company raised its 2025 sales guidance from $46.5 billion-$47.5 billion to $47.5 billion-$48 billion, above the consensus of $47.33 billion. Management attributed the increase primarily to continued strong performance of its Growth Portfolio, which includes newer treatments offsetting declines in legacy drugs facing generic competition.
BofA's upgrade reflects confidence that the market is underappreciating Bristol Myers' pipeline potential while overweighting near-term patent challenges. If the analyst is right, investors willing to look past the immediate headwinds could find value at current levels.
Bristol Myers shares rose 3.39% to $54.18 on Monday following the upgrade.
